Pharma · Public company · Tarrytown, NY, US

Regeneron Pharmaceuticals, Inc.

Ticker REGN · SEC CIK 0000872589

Track this companyFree. Adds Regeneron Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2525 recruiting or active

Pipeline programs46From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline46

Acetylsalicylic Acid (ASA)Phase 3 · Symptomatic Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
ALN-CIDEBPhase 3 · Metabolic Dysfunction-Associated Steatotic Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
ApixabanPhase 3 · Atrial Fibrillation (AF)ClinicalTrials.gov · fetched Nov 12, 2026
ApixabanPhase 3 · Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
CemdisiranPhase 3 · Age-related Macular Degeneration (AMD)ClinicalTrials.gov · fetched Nov 12, 2026
CemiplimabPhase 3 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
DexamethasonePhase 3 · Relapsed Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
ElotuzumabPhase 3 · Relapsed Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
EnoxaparinPhase 3 · Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
FianlimabPhase 3 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
FreneslerbartPhase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
LinvoseltamabPhase 3 · Relapsed Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
MevonlerbartPhase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 3 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
PomalidomidePhase 3 · Relapsed Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
PozelimabPhase 3 · Age-related Macular Degeneration (AMD)ClinicalTrials.gov · fetched Nov 12, 2026
REGN-2CatPhase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
REGN7508Phase 3 · Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
REGN7508Phase 3 · Atrial Fibrillation (AF)ClinicalTrials.gov · fetched Nov 12, 2026
REGN7508Phase 3 · Cancer-Associated Thrombosis (CAT)ClinicalTrials.gov · fetched Nov 12, 2026
REGN7508Phase 3 · Symptomatic Venous Thromboembolism (VTE)ClinicalTrials.gov · fetched Nov 12, 2026
REGN7508Phase 3 · Peripheral Artery Disease (PAD)ClinicalTrials.gov · fetched Nov 12, 2026
REGN9933Phase 3 · Peripheral Artery Disease (PAD)ClinicalTrials.gov · fetched Nov 12, 2026
REGN9933Phase 3 · Atrial Fibrillation (AF)ClinicalTrials.gov · fetched Nov 12, 2026
relatlimab+nivolumabPhase 3 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
RivaroxabanPhase 3 · Peripheral Artery Disease (PAD)ClinicalTrials.gov · fetched Nov 12, 2026
ALN-CIDEBPhase 2 · Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
BevacizumabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
CemiplimabPhase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
CemiplimabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
FianlimabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
Fianlimab+cemiplimabPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
LinvoseltamabPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
OlatorepatidePhase 2 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
OlatorepatidePhase 2 · Overweight or ObesityClinicalTrials.gov · fetched Nov 12, 2026
PLDPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
REGN5678Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)ClinicalTrials.gov · fetched Nov 12, 2026
SarilumabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
UbamatamabPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
BortezomibPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CarfilzomibPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
DaratumumabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
LenalidomidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
PomalidomidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
REGN20423Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
Non-InterventionalHemophilia BClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPHASE2 · RECRUITING · started Oct 29, 2026ClinicalTrials.gov NCT07830329 · fetched Nov 12, 2026
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE3 · RECRUITING · started Oct 28, 2026ClinicalTrials.gov NCT07854782 · fetched Nov 12, 2026
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersPHASE3 · RECRUITING · started Aug 26, 2026ClinicalTrials.gov NCT07493304 · fetched Nov 12, 2026
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPHASE3 · RECRUITING · started Aug 10, 2026ClinicalTrials.gov NCT07626411 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyPHASE3 · RECRUITING · started Jul 31, 2026ClinicalTrials.gov NCT07675811 · fetched Nov 12, 2026
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesPHASE2 · RECRUITING · started Jul 28, 2026ClinicalTrials.gov NCT07685808 · fetched Nov 12, 2026
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseasePHASE3 · RECRUITING · started Jul 10, 2026ClinicalTrials.gov NCT07318610 · fetched Nov 12, 2026
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)PHASE2 · RECRUITING · started Jul 6, 2026ClinicalTrials.gov NCT07631637 · fetched Nov 12, 2026
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisPHASE1 · RECRUITING · started May 22, 2026ClinicalTrials.gov NCT07527923 · fetched Nov 12, 2026
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePHASE3 · RECRUITING · started Apr 3, 2026ClinicalTrials.gov NCT07430956 · fetched Nov 12, 2026
REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisPHASE3 · RECRUITING · started Mar 9, 2026ClinicalTrials.gov NCT07410117 · fetched Nov 12, 2026
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPHASE3 · RECRUITING · started Nov 24, 2025ClinicalTrials.gov NCT07213778 · fetched Nov 12, 2026
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPHASE2 · RECRUITING · started Oct 20, 2025ClinicalTrials.gov NCT07175428 · fetched Nov 12, 2026
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsPHASE3 · RECRUITING · started Jun 25, 2025ClinicalTrials.gov NCT07015905 · fetched Nov 12, 2026
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerPHASE2 · RECRUITING · started May 28, 2025ClinicalTrials.gov NCT06787612 · fetched Nov 12, 2026
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 14, 2025ClinicalTrials.gov NCT06848088 · fetched Nov 12, 2026
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPHASE3 · RECRUITING · started Oct 30, 2024ClinicalTrials.gov NCT06541704 · fetched Nov 12, 2026
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)PHASE3 · RECRUITING · started Sep 9, 2024ClinicalTrials.gov NCT06246916 · fetched Nov 12, 2026
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement TherapyACTIVE_NOT_RECRUITING · started Jan 17, 2024ClinicalTrials.gov NCT05568459 · fetched Nov 12, 2026
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 19, 2023ClinicalTrials.gov NCT05828511 · fetched Nov 12, 2026
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaPHASE3 · RECRUITING · started Sep 18, 2023ClinicalTrials.gov NCT05730036 · fetched Nov 12, 2026
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 16, 2023ClinicalTrials.gov NCT05608291 · fetched Nov 12, 2026
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsPHASE1 · RECRUITING · started Aug 17, 2022ClinicalTrials.gov NCT05137054 · fetched Nov 12, 2026
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPHASE1_PHASE2 · RECRUITING · started Aug 12, 2019ClinicalTrials.gov NCT03972657 · fetched Nov 12, 2026
University of Michigan "Nephrology Research BioBank"RECRUITING · started Sep 1, 2006ClinicalTrials.gov NCT00381121 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Oct 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Sep 30, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Apr 8, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Feb 4, 2026 · fetched Nov 12, 2026